Effect of Common Medications on Breast Cancer-Related Lymphedema
NOTE: The article for this course is available through the Rehabilitation Oncology (RO) site; or in the Resources area of this course.
The purpose of this course is to provide clinicians with a greater understanding of the impact of common medications on breast cancer-related lymphedema.
Primary Author bio:
Emily Tesar, MSN, RN, OCN is an experienced oncology nurse and nurse educator. She has practiced in a variety of nursing settings, including as an oncology nurse patient navigator and regional care navigator in Montana. She holds a Masters of Science in Nursing and completed this review as part of her doctoral studies at University of Missouri.
Dr. Jane Armer is Professor, University of Missouri Sinclair School of Nursing, and founding Director, American Lymphedema Framework Project, a national organization housed at University of Missouri which aims to increase awareness of lymphedema and improve care for persons with lymphedema in the US and around the world. She focuses her research on the more-than-3-million breast cancer survivors who are at risk for lymphedema. She has conducted extensive work in lymphedema incidence and prevalence; signs and symptoms; fatigue; and self-management of chronic illness. She has expertise in anthropometric measurements and lymphedema management.
cert_Insert Up To
cert_NV credit value
Upon completion of this OncoRead course, the learner will be able to:
- Describe the EDGE task force systematic review process to evaluate and recommend clinical measures for pain in patients with cancer.
- Describe important criteria for evaluating and selecting clinical measures of pain for use in clinical practice.
- Utilize the EDGE task force recommendations to select measures of pain in an oncology practice setting.
- Describe the psychometric properties for recommended clinical measures of pain.
Sponsored by logo
Brought to you by
- Non Member$100.00(until 12/31/2030)
- Member$60.00(until 12/31/2030)
- Oncology$54.00(until 12/31/2030)